Publications

2019

S Tadayon, J Dunkel, A Takeda, O Halle, M Karikoski, H Gerke, P Rantakari, R Virtakoivu, O Pabst, M Salmi, M Hollmén*, S Jalkanen*. Clever-1 contributes to lymphocyte entry into the spleen via the red pulp. Science Immunology, Vol. 4, Issue 33, eaat0297. DOI: 10.1126/sciimmunol.aat0297. *equal contribution

M Viitala, R Virtakoivu, S Tadayon, J Rannikko, S Jalkanen, M Hollmén. Immunotherapeutic Blockage of Macrophage Clever-1 Reactivates the CD8+ T Cell Response Against Immunosuppressive Tumors. Clin Can Res 2019. In press. http://clincancerres.aacrjournals.org/content/early/2019/02/12/1078-0432.CCR-18-3016.abstract

2018

J Jalkanen, M Hollmén, M Maksimow, S Jalkanen, H Hakovirta. Serum cytokine levels differ according to major cardiovascular risk factors in patients with lower limb atherosclerosis. Cytokine 2018 Nov 13. pii: S1043-4666(18)30413-7.

J Dunkel, M Viitala, M Karikoski, P Rantakari, R Virtakoivu, K Elima, M Hollmén, Sirpa Jalkanen, Marko Salmi. Enhanced Antibody Production in Clever-1/Stabilin-1–deficient mice. Front. Immunol. 2018 Oct 8;9:2257.

E Munukka, J Ahtiainen, P Puigbo, S Jalkanen, K Pahkala, A Rintala, UM Kujala, M Hollmén, P Huovinen, G D’Auria, S Pekkala. Six-week endurance exercise alters gut metagenome that is not reflected in systemic metabolism in over-weight women. Front. Microbiol. 2018 Oct 3;9:2323 | https://doi.org/10.3389/fmicb.2018.02323

A Keskitalo, E Munukka, R Toivonen, M Hollmén, H Kainulainen, P Huovinen, S Jalkanen, S Pekkala. Enterobacter cloacae administration induces hepatic damage and subcutaneous fat accumulation in high-fat fed mice. PLoS ONE 2018, 30;13(5):e0198262. Doi: 10.1371/journal .pone.0198262.

P Rinne, JJ Kadiri, M Velasco-Delgado, S Nuutinen, M Viitala, M Hollmén, M Rami, E Savontaus, S Steffens. Melanocortin 1 Receptor Deficiency Promotes Atherosclerosis in Apolipoprotein E-/- Mice. Arteriosclerosis, Trombosis and Vascular Biology, 2018, Feb 38(2):313-323. doi: 10.1161/ATVBAHA.

2017

J Cui, M Hollmén, Li Lina, Y Chen, S Proulx, D Reker, G Schneider, M Detmar. New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate. Oncotarget, 2017 Jan 3;8(1):1007-1022. doi: 10.18632/oncotarget.13537.

J Jalkanen, M Hollmén, Sirpa Jalkanen, H Hakovirta. Regulation of CD73 in the Development of Lower Limb Atherosclerosis. Purinergic Signalling, 2017 Mar;13(1):127-134. doi: 10.1007/s11302-016-9545-0.

2016

S Vaara, M Hollmén, A-M Korhonen, M Maksimow, T Ala-Kokko, M Salmi, S Jalkanen, V Pettilä, The FINNAKI Study Group. Soluble CD73 in critically ill septic patients – data from the prospective FINNAKI study. PLoS ONE, 2016 Oct 12;11(10):e0164420. doi: 10.1371/journal.pone.0164420.

J Jalkanen, M Maksimow, M Hollmén, S Jalkanen, H Hakovirta. Compared to Intermittant Claudication Critical Limb Ischemia is Associated with Elevated Levels of Cytokines. PLoS ONE, 2016 Sep 9;11(9):e0162353. doi: 10.1371/journal.pone.0162353.

S Karaman, M Hollmén, S-Y Yoon, HF Alkan, K Alitalo, C Wolfrum, M Detmar. Transgenic overexpression of VEGF-C induces weight gain and insulin resistance in mice. Scientific Reports, 2016 Aug 11;6:31566. doi: 10.1038/srep31566.

AJ Christiansen, LC Dieterich, I Ohs, S Bachmann, R Bianchi, ST Proulx M Hollmén, D Aebischer, M Detmar. Lymphatic endothelial cells attenuate inflammation via suppression of dendritic cell maturation. Oncotarget 2016 Jun 5. doi: 10.18632/oncotarget.9820.

F Roudnicky, M Hollmén. Transcriptional profiling of macrophage and tumor cell interactions in vitro. Genomics data 2016, 8;1–3 doi:10.1016/j.gdata.2016.02.009 

2015 

M Hollmén, S Karaman, S Schwager, A Lisibach, AJ Christiansen, M Maksimow, Z Varga, S Jalkanen and M Detmar. G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer. Oncoimmunology 11/2015, doi: 10.1080/2162402X.2015.1115177.

Li X, Martinez-Lozano Sinues P, Dallmann R, Bregy L, Hollmén M, Proulx S, Brown SA, Detmar M, Kohler M and Zenobi R. Drug Pharmacokinetics Determined by Real-Time Analysis of Mouse Breath. Angew Chem Int Ed Engl 2015, 4(27):7815-8. doi: 10.1002/anie.201503312. 

M Hollmén, F Roudnicky, S Karaman and M Detmar. Characterization of macrophage – cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer. Scientific Reports 3/2015 doi:10.1038/srep09188.

J Jalkanen, GG Yegutkin, M Hollmén, K Aalto, T Kiviniemi, V Salomaa, S Jalkanen, H Hakovirta. Aberrant Circulating Levels of Purinergic Signaling Markers are Associated with Several Key Aspects of Peripheral Atherosclerosis and Thrombosis. Circulation Research 2/2015 doi: 10.1161/CIRCRESAHA.116.305715.

2014

S Karaman, M Hollmén, MR Robciuc, A Alitalo, H Nurmi, B Morf, D Buschle, HF Alkan, AM Ochsenbein, K Alitalo, C Wolfrum and M Detmar. Blockade of VEGF-C and VEGF-D modulates adipose tissue inflammation and improves metabolic parameters under high-fat diet. Molecular Metabolism 12/2014; doi: 10.1016/j.molmet.2014.11.006.

GG Yegutkin, K Auvinen, P Rantakari, M Hollmén, M Karikoski, R Grénman, K Elima, S Jalkanen and M Salmi. Ecto-5′-nucleotidase/CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature.. Eur J Immunol 7/2014 doi: 10.1002/eji.201444856.

M Karikoski, F Marttila-Ichihara, K Elima, P Rantakari, M Hollmén, T Kelkka, H Gerke, V Huovinen, H Irjala, R Holmdahl, M Salmi and S Jalkanen. Clever-1/Stabilin-1 Controls Cancer Growth and Metastasis. Clin Can Res 10/2014 doi: 10.1158/1078-0432.CCR-14-1236.

He JJ, Martinez-Lozano Sinues P, Hollmén M, Li X, Detmar M and Zenobi R.  Fingerprinting Breast Cancer vs. Normal Mammary Cells by Mass Spectrometric Analysis of Volatiles. Scientific Reports 2014, 4:5196.

2013

N Valtcheva, A Primorac, G Jurisic, M Hollmén and M Detmar. The orphan adhesion G protein coupled receptor GPR97 regulates migration of lymphatic endothelial cells via the small GTPases RhoA and Cdc42. J Biol Chem 2013, 288:35736-48.

2012

M Hollmén, P Liu, K Kurppa, H Wildiers, I Reinvall, T Vahlberg, T van Dorpe, A Smeets, K Deraedt, H Joensuu, D Leahy, P Schöffski and K Elenius. Proteolytic processing of ErbB4 in breast cancer. PLoS ONE 2012, 7(6): e39413.

2005-2010

M Hollmén and K Elenius. Potential of ErbB4 antibodies for cancer therapy. Future Oncology 2010, 6:37-53, Review.

K Peltola, M Hollmén, S-M Maula, E Rainio, R Ristamäki, M Luukkaa, J Sandholm, M Sundvall, K Elenius, PJ Koskinen, R Grenman and S Jalkanen. Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor. Neoplasia 2009, 11:629-36.

M Hollmén, J Määttä, L Bald, MX Sliwkowski and K Elenius. Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. Oncogene 2009, 28:1309-19. *patent

D Tvorogov, M Sundvall, K Kurppa, M Hollmén, S Repo, M Johnsson and K Elenius. Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer. J Biol Chem 2009, 284:5582-91.

Tanner M, Hollmén M, Junttila TT, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K and Isola J. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis, and sensitivity to trastuzumab. Annals of Oncology 2005, 16:273-278.